Biosimilars – Talk Bio

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

1 week ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

2 months ago talkbio0Tagged Bioepis, Biosimilars, Contract agreement, Johnson and Johnson, Pyzchiva, Samsung, Stelara, ustekinumab

Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

2 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma

Amgen and Celltrion Reach Settlement in Denosumab Patent Litigation, Paving Way for Mid-2025 Biosimilar Launch

3 months ago talkbio0Tagged amgen, Biosimilars, Celltrion, denosumab, launch, Legal patent, Litigation, settlement

Amgen, Celltrion, denosumab, patent litigation, biosimilar, settlement, launch date

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

3 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook

4 months ago talkbio0Tagged 2024, Biopharmaceutical manufacturing, Biosimilars, Biotechnology, Cells, Drug Discovery, gene therapy, innovations, Precision Medicine, trends qualifier

Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

4 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset

5 months ago talkbio0Tagged Biosciences, Biosimilars, Biotechnology, Coherus, Drug Industry, strategic pivot

Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology

Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption

7 months ago talkbio0Tagged Biosciences, Biosimilars, Cancer Therapeutic Procedure, Coherus, Disruption, Neulasta, pegfilgrastim, Pharmaceutical Supply Chain, Udenyca, White Blood Cell Count procedure

UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.